<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Phil</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Davison, Beth A.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Adding Clarity to Worsening HF</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-07-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">17-18</style></pages><abstract><style  face="normal" font="default" size="100%">This article presents the results of a pooled analysis that addressed several questions concerning worsening heart failure (HF). The meta-analysis was based on patient-level data (n=3733) from 4 studies: the RELAX-AHF [Relaxin for the Treatment of Acute Heart Failure; Teerlink JR et al. Lancet 2013], the Pre-RELAX-AHF [Teerlink JR et al. Lancet 2009], the PROTECT pilot study [Pro-BNP Outpatient Tailored Chronic Heart Failure Therapy; Cotter G et al. J Cardiac Fail 2008], and PROTECT [Massie BM et al. N Engl J Med 2010].</style></abstract><number><style face="normal" font="default" size="100%">12</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>